Fig. 3: Prognostic assessment of ctDNA detection at baseline and mid-NAT. | Nature Communications

Fig. 3: Prognostic assessment of ctDNA detection at baseline and mid-NAT.

From: Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Fig. 3

A Baseline ctDNA detection and association with RFI (HR: 2.89, 95% CI: 1.003–8.31; Log-rank (Mantel–Cox) p = 0.049). B Mid-NAT ctDNA detection and association with RFI in all participants (HR: 3.59, 95% CI: 0.99–12.87; Log-rank (Mantel–Cox) p = 0.050). C Mid-NAT ctDNA detection and association with RFI in participants with HER2-negative disease (HR: 14.43, 95% CI: 3.00–69.53; Log-rank (Mantel-Cox) p = 0.0009). HR hazard ratio, 95% CI: 95% confidence interval, NR not reached.

Back to article page